

15. The composition of claim 9, wherein the stabilizers are selected from the group consisting of antioxidation agents, buffers, and acids.

16. A method for treating rosacea in a mammal in need thereof, comprising administering an oral pharmaceutical composition consisting of (i) an immediate release formulation (IR) comprising about 30 mg doxycycline; a delayed release formulation (DR) comprising about 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients.

17. A method for treating rosacea in a mammal in need thereof, comprising administering an oral pharmaceutical composition comprising doxycycline, which at a once-daily dosage will give blood levels of the doxycycline of a minimum of 0.1 µg/ml and a maximum of 1.0 µg/ml, the composition consisting of (i) an immediate release formulation (IR) comprising about 30 mg doxycycline; as a delayed release formulation (DR) comprising about 10 mg doxycycline; and optionally, (iii) one or more pharmaceutically acceptable excipients.

18. The method of claim 17, wherein the mammal is a human.

19. The method of claim 17, which at a once-daily dosage, administration of the composition will give blood levels of the doxycycline of between 0.3 µg/ml to 0.8 µg/ml.

* * * * *